journal
MENU ▼
Read by QxMD icon Read
search

Oncology Research and Treatment

journal
https://www.readbyqxmd.com/read/27889787/stratified-treatment-in-lung-cancer
#1
Sebastian Michels, Jürgen Wolf
Even though great efforts have been made to improve chemotherapy-based treatment approaches for lung cancer, the prognosis of patients with advanced and metastasized disease remains particularly poor. In recent years, a growing number of genetic aberrations driving lung cancer have been identified. Targeted inhibition of some of these aberrations, most prominently mutated EGFR and ALK, by tyrosine kinase inhibitors has dramatically increased efficacy and tolerability of systemic lung cancer treatment in subsets of patients...
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/27889786/targeted-therapy-of-colorectal-cancer
#2
Andreas Seeber, Günther Gastl
Over the past decades, considerable progress has been made in the management of colorectal cancer (CRC), leading to a significant improvement in overall survival. Although part of this success has been rightly attributed to aggressive surgical management and advances in other adjunct treatments, our understanding of the pathogenesis of CRC and emergence of newer molecular targets for colon cancer has created a powerful impact. In this review article, we will discuss various targeted therapies in the management of metastatic CRC (mCRC)...
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/27889785/overcoming-cost-implications-of-mutational-analysis-in-patients-with-gastrointestinal-stromal-tumors-a-pragmatic-approach
#3
Patrick Schöffski, Agnieszka Wozniak, Oliver Schöffski, Liesbet van Eycken, Maria Debiec-Rychter
BACKGROUND: Genetic analysis of tissue derived from patients with advanced gastrointestinal stromal tumors (GISTs) is not uniformly applied on a national and international level, even though mutational data can provide clinically relevant prognostic and predictive information, especially in patients qualifying for treatment with expensive targeted agents. METHODS: The current article describes the rationale for genetic testing of GIST tissue, looks at financial implications associated with such analysis and speculates on potential cost savings introduced by routine mutational testing and tailored use of tyrosine kinase inhibitors based on genotyping...
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/27889784/targeted-therapy-of-cll
#4
Othman Al-Sawaf, Kirsten Fischer, Barbara Eichhorst, Michael Hallek
The landscape of chronic lymphocytic leukemia (CLL) has undergone profound changes in the past years. First, the addition of CD20-targeting antibodies to conventional chemotherapy has improved the therapeutic outcome in the majority of CLL patients. Since the establishment of the critical role of the B cell receptor signaling pathway in the pathogenesis of CLL, several agents have been developed to target this pathway. Ibrutinib and idelalisib, 2 potent kinase inhibitors, have both become available for CLL therapy in the first and second line...
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/27889783/advances-in-cancer-therapy-targeted-therapies
#5
Dieter Marmé
No abstract text is available yet for this article.
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/27889782/molecular-pathology-a-requirement-for-precision-medicine-in-cancer
#6
Manfred Dietel
The increasing importance of targeting drugs and check-point inhibitors in the treatment of several tumor entities (breast, colon, lung, malignant melanoma, lymphoma, etc.) and the necessity of a companion diagnostic (HER2, (pan)RAS, EGFR, ALK, BRAF, ROS1, MET, PD-L1, etc.) is leading to new challenges for surgical pathology. Since almost all the biomarkers to be specifically detected are tissue based, a precise and reliable diagnostic is absolutely crucial. To meet this challenge surgical pathology has adapted a number of molecular methods (semi-quantitative immunohistochemistry, fluorescence in situ hybridization, PCR and its multiple variants, (pyro/Sanger) sequencing, next generation sequencing (amplicon, whole exome, whole genome), DNA arrays, methylation analyses, etc...
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/27889780/targeted-treatment-of-esophagogastric-cancer
#7
Hans-Georg Kopp, Ralf-Dieter Hofheinz
Adenocarcinoma of the esophagogastric junction (EGJ) and stomach remains one of the most common causes of cancer-related death worldwide. Although there is increasing data on the mutational landscape of esophagogastric cancer, phase III trials often yield negative results, and there is a paucity of approved targeted agents. For the time being, the subset of patients carrying HER2-positive metastatic tumors can receive trastuzumab in addition to chemotherapy. Furthermore, ramucirumab has been found to be active both as a single agent and in combination with paclitaxel...
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/27889778/primary-intestinal-hodgkin-lymphoma-mimicking-intraabdominal-abscess-in-a-renal-transplant-recipient-a-case-report
#8
Biljana Mihaljevic, Darko Antic, Vojin Vukovic, Maja Perunicic Jovanovic, Visnja Lezaic, Nemanja Zaric, Mirko Kerkez, Vladimir Djordjevic
INTRODUCTION: Post-transplant lymphoproliferative disease (PTLD) comprises a variety of lymphoid and plasma cell disorders arising in patients with a solid organ transplant. Monomorphic lymphomas represent the most significant part of this wide spectrum, with the overall risk rising with the aggressiveness of lymphoid proliferation in comparison to the general population. The development of Hodgkin lymphoma is very rare in transplant recipients, comprising less than 6% of all monomorphic PTLD, while cases of primary intestinal Hodgkin lymphoma in these circumstances are anecdotal...
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/27889751/targeted-therapy-of-head-and-neck-cancer
#9
Damian T Rieke, Konrad Klinghammer, Ulrich Keilholz
Head and neck squamous cell carcinoma (HNSCC) is one of the most common solid cancers worldwide. It is mainly caused by exposure to tobacco smoke and alcohol as well as infection with the human papilloma virus (HPV). The prognosis is poor, especially once it recurs or metastasizes. Current therapeutic options include surgery, radio- and chemotherapy. Epidermal growth factor receptor (EGFR) inhibitors are so far the only targeted agents that have been approved in head and neck cancer. Primary or secondary resistance is frequent or will eventually develop...
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/27855414/clinical-characteristics-and-treatment-outcomes-of-patients-with-primary-mediastinal-germ-cell-tumors-10-years-experience-at-a-single-institution-with-a-bleomycin-containing-regimen
#10
Arunee Dechaphunkul, Siwat Sakdejayont, Chirawadee Sathitruangsak, Patrapim Sunpaweravong
BACKGROUND: Cisplatin-based chemotherapy followed by surgical resection of the residual tumor remains the standard of care for patients with mediastinal germ cell tumors (MGCTs). To prevent pulmonary complications, a non-bleomycin-containing regimen is generally preferred. This study aims to review the clinical characteristics and outcomes of these patients. METHODS: A retrospective chart review was undertaken in patients treated for MGCTs between 2003 and 2013...
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/27855388/association-between-ki67-index-and-clinicopathological-features-in-colorectal-cancer
#11
Pan Li, Zhi-Tao Xiao, Todd A Braciak, Qing-Jan Ou, Gong Chen, Fuat S Oduncu
BACKGROUND: Conflicting results have been reported about the association between the Ki67 labeling index (Ki67-Li) and clinical outcome in patients with colorectal cancer (CRC). PATIENTS AND METHODS: Ki67 expression was assessed by immunohistochemistry (IHC) in 2,233 consecutive CRC cases. RESULTS: We determined 992 cases to have a low and 1,241 cases to have a high Ki67-Li (representing an approximately 44-56% breakdown in distribution between low versus high patients designated by phenotype)...
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/27855386/conversion-of-platinum-etoposide-resistant-to-sensitive-sclc-after-treatment-with-the-epi-immunotherapeutic-rrx-001-a-case-report
#12
Christina Brzezniak, Bryan Oronsky, Jan Scicinski, Scott Caroen, Pedro Cabrales, Nacer Dean Abrouk, Michelle M Kim, James F Brown, Tony R Reid, Christopher Larson, Arnold Oronsky, Regina Day, Aiste Degesys, Corey A Carter
BACKGROUND: The response to first-line platinum doublets (cisplatin/etoposide) in small-cell lung cancer (SCLC) predicts the probability of subsequent response to second-line therapy. In general, the longer-lived the responses in first line, the better the outcome in second line, with the opposite prognosis for shorter-lived responses. Resistant SCLC is defined as relapse within 90 days of platinum-doublet treatment, and predictably correlates with shortened survival compared with sensitive disease, defined as relapse after 90 days...
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/27855385/prognostic-significance-of-preoperative-prognostic-nutritional-index-in-epithelial-ovarian-cancer-patients-treated-with-platinum-based-chemotherapy
#13
Yi Miao, Shuangdi Li, Qin Yan, Bilan Li, Youji Feng
BACKGROUND: The aim of present study was to investigate the role of the prognostic nutritional index (PNI) used as a prognostic marker for predicting response and survival outcomes in patients with epithelial ovarian cancer (EOC) who are receiving platinum-based chemotherapy. PATIENTS AND METHODS: Patients with a new diagnosis of EOC receiving postoperative platinum-based chemotherapy were identified. The PNI was calculated as 10 × serum albumin value (g/dl) + 0...
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/27855384/asco-2016-immuntherapie-bringt-weitere-fortschritte-bei-hautkrebs
#14
(no author information available yet)
No abstract text is available yet for this article.
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/27855383/clinical-aspects-and-prognostic-factors-for-survival-in-patients-with-recurrent-cervical-cancer-after-radical-hysterectomy
#15
Jitti Hanprasertpong, Ingporn Jiamset, Alan Geater, Athithan Rattanaburi, Sarayut Thannil
BACKGROUND: The aim of this study was to investigate the clinical aspects and prognostic factors for survival in patients with recurrent cervical cancer after radical hysterectomy with node dissection (RHND) for stages IA2-IB1. PATIENTS AND METHODS: Clinicopathologic characteristics of the primary tumor, pattern of recurrence, method of detection, salvage treatment, and outcome were reviewed from the medical records of patients who underwent RHND between 1987 and 2015...
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/27855381/multiples-myelom-asco-2016-best%C3%A3-tigung-der-aszt-und-neue-daten-zur-systemischen-therapie
#16
(no author information available yet)
No abstract text is available yet for this article.
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/27855379/suvmax-and-tumour-location-in-pet-ct-predict-oncogene-status-in-lung-cancer
#17
Paul M Putora, Kinga Szentesi, Markus Glatzer, Regulo Rodriguez, Joachim Müller, Florent Baty, Martin Früh
BACKGROUND: In non-small cell lung cancer, anaplastic lymphoma kinase gene rearrangement (ALK+) and epidermal growth factor receptor mutations (EGFR+) are targetable with tyrosine kinase inhibitors. PATIENTS AND METHODS: 27 patients with ALK+ tumours, who underwent positron emission tomography-computed tomography (PET-CT) prior to any treatment, were identified. 2 equally sized control groups based on consecutive patients with EGFR+ and EGFR/ALK wild-type (wt) were identified...
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/27855378/communication-before-cancer-surgery-the-perspective-of-patients-with-gastrointestinal-cancer
#18
Jutta Huebner, Christian Keinki, Juergen Kleeberg, Eckart Seilacher
No abstract text is available yet for this article.
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/27780171/-vorwort
#19
Axel Hauschild, Dirk Schadendorf
No abstract text is available yet for this article.
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/27780162/-entscheidungsfindung-f%C3%A3-r-die-klinische-praxis-aktuelle-konzepte-und-behandlungsalgorithmen-mit-immun-checkpoint-inhibitoren-beim-melanom
#20
Dirk Schadendorf
No abstract text is available yet for this article.
2016: Oncology Research and Treatment
journal
journal
48348
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"